A data infrastructure dedicated to Long-Acting Injectables. Vectora maps the field — drugs, candidates, trademarks, delivery technologies and indications — from public sources, and keeps it up to date, with every regulatory fact linked to its official FDA or EMA label.
It lives across FDA filings, ClinicalTrials.gov, PubMed and corporate press, and no generalist platform gives the niche a formal scope. So the work of reassembling it — source by source, name by name — falls on the analyst.
Two layers, kept in sync. One holds the current state of the LAI landscape — every company, drug, candidate and technology. The other tracks the events that change it: trials, approvals, deals. Each event links to what it affects, so the news and the structure stay connected.
An explicit, versioned definition of the niche: which drugs, candidates, trademarks, companies and indications qualify as long-acting injectable. The scope is a documented editorial decision — reviewable, not a keyword match.
Technologies classified across physical and chemical release families and half-life-extension mechanisms — independent axes that combine. So you can isolate, say, ester prodrugs formulated as nanocrystals.
The system captures events — trials, approvals, deals, publications — and maintains the state of each entity. Every event is linked to the players it involves, so signals and structure stay connected.
Regulatory facts link to their official FDA and EMA documents. Every other value is captured from public sources and organized into one consistent ontology.
Every company, marketed drug, clinical candidate, trademark, proprietary delivery technology, target and indication in the LAI field — modeled as a queryable ontology, built from public sources: FDA, EMA, ClinicalTrials.gov, PubMed, corporate.
Each asset is a molecule × delivery technology × developer. Size the landscape and segment it — by phase, technology, target or modality.
Each product is a brand × authority. Read the real regulatory profile — FDA against EMA, label by label.
An interactive view of the LAI landscape. Scope a population of assets, then read it through a lens: a table, a competitive landscape, market trends over time, a positioning map — and a side-by-side comparison of two to six items, FDA against EMA.
Sourced by default. Regulatory facts link to their official FDA and EMA labels — and no value is ever invented to fill a blank.
The same substrate, read through the lens of each role.
Vectora encodes that domain work — the scope, the ontology, the delivery-technology taxonomy — into the substrate itself. In a specialized field, the analysis is only as strong as the domain knowledge behind it.
You work directly with the analyst who builds and maintains the substrate — not an account manager relaying your questions.
One substrate feeds all three products, each unlocked for your organization as it becomes available.
Explore the landscape. Scope a population, compare molecules or products, read FDA against EMA in one view.
A periodic brief of LAI events — readouts, approvals, deals — filtered to the niche.
Briefs and reports generated on demand — each claim traceable to its source.
Vectora is opening to a first group of LAI teams as design partners. Tell us about your work and we’ll be in touch.
Request access